Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Current Leases (2019 - 2025)

BeOne Medicines (BEIGF) has disclosed Current Leases for 7 consecutive years, with $20.7 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 17.76% to $20.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.7 million through Dec 2025, up 17.76% year-over-year, with the annual reading at $20.7 million for FY2025, 17.76% up from the prior year.
  • Current Leases for Q4 2025 was $20.7 million at BeOne Medicines, up from $15.7 million in the prior quarter.
  • The five-year high for Current Leases was $24.8 million in Q2 2022, with the low at $14.0 million in Q1 2021.
  • Average Current Leases over 5 years is $20.2 million, with a median of $20.0 million recorded in 2024.
  • The sharpest move saw Current Leases skyrocketed 63.61% in 2022, then fell 24.89% in 2024.
  • Over 5 years, Current Leases stood at $21.9 million in 2021, then grew by 9.65% to $24.0 million in 2022, then decreased by 8.7% to $22.0 million in 2023, then decreased by 19.93% to $17.6 million in 2024, then increased by 17.76% to $20.7 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $20.7 million, $15.7 million, and $17.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.